Of note, one trial, the Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post-Worsening Heart Failure (SOLOIST-WHF) trial [64] enrolled subjects with T2DM and a recent hospitalization for acute decompensation of HF, therefore, it did not assess the safety and efficacy of SGLT-2 inhibitors in the “strict” setting of acute HF. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.